Seborrhea - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Seborrhea - Pipeline Review, H2 2016

Seborrhea - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Seborrhea - Pipeline Review, H2 2016
Published Aug 24, 2016
40 pages — Published Aug 24, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Seborrhea - Pipeline Review, H2 2016, provides an overview of the Seborrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seborrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Seborrhea
- The report reviews pipeline therapeutics for Seborrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Seborrhea therapeutics and enlists all their major and minor projects
- The report assesses Seborrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Seborrhea


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Seborrhea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Seborrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing stra

  
Source:
Document ID
GMDHC8383IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Seborrhea Overview61
Therapeutics Development71
  Pipeline Products for Seborrhea Overview71
Seborrhea Therapeutics under Development by Companies81
Seborrhea Pipeline Products Glance93
  Late Stage Products91
  Clinical Stage Products101
  Early Stage Products111
Seborrhea Products under Development by Companies121
Seborrhea Companies Involved in Therapeutics Development135
  Aclaris Therapeutics Inc131
  Amorepacific Corporation141
  Biomar Microbial Technologies151
  EpiPharm AG161
  Phosphagenics Limited171
Seborrhea Therapeutics Assessment188
  Assessment by Monotherapy Products181
  Assessment by Target192
  Assessment by Mechanism of Action212
  Assessment by Route of Administration232
  Assessment by Molecule Type251
Drug Profiles268
  artemether Drug Profile261
  hydrogen peroxide Drug Profile272
  IB-07A081 Drug Profile291
  IB-07A085 Drug Profile301
  ketoconazole Drug Profile311
  PAC-14028 Drug Profile322
Seborrhea Dormant Projects341
Seborrhea Discontinued Products351
Seborrhea Product Development Milestones363
  Featured News &Press Releases361
    Jul 25, 2016: Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis; Provides Update on Clinical Programs361
    Jan 19, 2016: Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis361
    Mar 17, 2015: Aclaris Therapeutics Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor361
    Jan 27, 2015: Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor371
    Jun 30, 2014: Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor381
Appendix392
  Methodology391
  Coverage391
  Secondary Research391
  Primary Research391
  Expert Panel Validation391
  Contact Us391
  Disclaimer401

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Seborrhea - Pipeline Review, H2 2016" Aug 24, 2016. Alacra Store. May 15, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Seborrhea-Pipeline-Review-H2-2016-2088-16425>
  
APA:
Global Markets Direct - Market Research. (2016). Seborrhea - Pipeline Review, H2 2016 Aug 24, 2016. New York, NY: Alacra Store. Retrieved May 15, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Seborrhea-Pipeline-Review-H2-2016-2088-16425>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.